<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00624923</url>
  </required_header>
  <id_info>
    <org_study_id>CHS 06-13</org_study_id>
    <secondary_id>P50HL083813</secondary_id>
    <secondary_id>CCI: 2006-P-00175</secondary_id>
    <secondary_id>CHS: 06-13</secondary_id>
    <nct_id>NCT00624923</nct_id>
  </id_info>
  <brief_title>Targeting Inflammation Using Salsalate in CardioVascular Disease</brief_title>
  <acronym>TINSAL-CVD</acronym>
  <official_title>Targeting Inflammation Using Salsalate in CardioVascular Disease (TINSAL-CVD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joslin Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Joslin Diabetes Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is that western lifestyle, with sedentary behaviors and caloric excess promote
      a chronic, subacute inflammatory state that participates in the development and progression
      of atherosclerosis. We will evaluate the effects of targeting inflammation using the
      anti-inflammatory drug salsalate, compared to placebo, on coronary artery plaque volume
      assessed by multi-detector computed tomographic angiography (MDCTA). The TINSAL-CVD study is
      a randomized, double-masked, placebo-controlled, 2 arm, clinical trial.

      The purpose of the study is to compare the effect of salsalate or placebo on sub-acute
      inflammation and coronary plaque, in people with cardiovascular disease. Participants are
      randomized to active intervention (salsalate) or placebo interventions for a period of 30
      months. The primary endpoint is change in plaque volume in the coronary arteries assessed by
      MDCTA from baseline to 30 months.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2008</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Non-calcified Plaque Volume in the Coronary Arteries Assessed by MDCTA From Baseline to 30 Months</measure>
    <time_frame>Baseline to 30 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Metabolic Syndrome Assessed by Measures by Waist/Hip Ratio, Systolic and Diastolic Blood Pressure, Lipid Profiles (Total Cholesterol, Triglycerides, HDL and LDL), and Abdominal Adiposity Quantitated by Computerized Tomography</measure>
    <time_frame>Baseline to 30 mo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of Mediators of Inflammation in the Circulation (Such as CRP), and Markers of Oxidative Stress.</measure>
    <time_frame>baseline to 30 mo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of Insulin Resistance Assessed by Fasting Insulin and Homeostasis Model Assessment of Insulin Resistance (HOMA-IR).</measure>
    <time_frame>baseline to 30 mo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of Inflammation in the Liver Associated With Nonalcoholic Steatohepatitis (NASH), and Reduction of Fatty Liver Quantitated by Computerized Tomography and Levels of AST and ALT as Markers of Liver Inflammation Related to NASH.</measure>
    <time_frame>baseline to 30 mo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Rates of Addition of Anti-hypertensive, Diabetic, or Lipid Lowering Medication.</measure>
    <time_frame>baseline to 30 mo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Numbers of Persons With Metabolic Syndrome Who Progress to Diabetes Between Groups.</measure>
    <time_frame>baseline to 30 mo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Numbers of Persons Who Regress From ATPIII Metabolic Syndrome Criteria (for Those With Metabolic Syndrome at Baseline)</measure>
    <time_frame>baseline to 30 mo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Vitamin D Status and Coronary Calcification, as Well as With Insulin Resistance (HOMA-IR), Beta-cell Function (HOMA-%Beta), and Serum Levels of Inflammatory Cytokines and Adhesion Molecules, Known to be Related to CVD Risk.</measure>
    <time_frame>Baseline evaluation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of Whether Baseline Vitamin D Levels Predict Clinical Response to Salsalate, and Whether Hypovitaminosis D is Associated With Plaque Progression.</measure>
    <time_frame>baseline to 30 mo</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">340</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>1- Active Pharmacologic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Salsalate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salsalate</intervention_name>
    <description>Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months</description>
    <arm_group_label>1- Active Pharmacologic</arm_group_label>
    <other_name>disalcid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched to Salsalate, seven tablets daily by mouth, divided into two doses, for 30 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Eligibility will be based upon the presence of established coronary artery disease
        including

          -  previous myocardial infarction (≥6 months ago), or

          -  previous coronary bypass surgery (&gt; 12 months ago), or

          -  stable angina, or

          -  significant non-calcified plaque in at least one coronary artery, or

          -  abnormal exercise tolerance test or

          -  an area of reversible ischemia on nuclear imaging study or pharmacologic stress, with
             subsequent revascularization, or angioplasty, or

          -  abnormal exercise treadmill stress test with or without nuclear imaging or
             echocardiography with the following exclusions:

        Exclusions based on nuclear imaging:

          1. Transient cavity dilation

          2. More than one vascular territory involved with reversible defect (multiple defects)

          3. Reversible defects involving the anterior wall, septum or apex (LAD territory)

        Exclusions based on echocardiography imaging:

          1. More than one vascular territory involved with inducible wall motion abnormalities
             (multiple defects)

          2. Inducible wall motion abnormalities involving the anterior wall, septum or apex (LAD
             territory)

        Subjects should be at list 6 months after a myocardial infarction and/or revascularization
        procedure to be eligible.

        In addition, subjects must be:

          1. aged 21- 75 years inclusive,

          2. BMI ≥ 27 kg/m2 and ≤ 35 kg/m2 if female and ≤ 40 kg/m2 if male (a BMI ≥24.5 for
             subjects from Asian origin)

          3. on a stable dose of an HMG CoA reductase inhibitor (statin) for 1 month at screening
             or unable to tolerate a statin,

          4. have normal renal function, (note estimated creatinine clearance calculated using
             Cockcroft-Gault (CG) equation ≥60 at screening [eCrCLCG (ml/min) = [(140 - age) x
             weight (kg)]/[SCr(mg/dl) x 72] x [0.85 if female],

          5. have liver function (ALT, AST) &lt; 3 times upper limits of normal),

          6. normal thyroid function (on stable dose replacement therapy is acceptable),

          7. if women are of child bearing potential they must have a pregnancy test prior to the
             CT angio and use contraception for the remainder of the study

          8. patients with T2D must have a fasting glucose of ≤ 200 mg/dl at screening and cannot
             be treated with thiazolidinedione class agents or insulin or Extendin-4 (Byetta)
             therapy.

        Subjects must be willing to have at least three visits at the Beth Israel-Deaconess Medical
        Center/Joslin Diabetes Center with a baseline and a 30-month follow-up series of imaging
        studies including CT angiography of the coronary arteries and imaging of the aorta,
        abdominal adiposity and liver, and interim visit at 1 year.

        Exclusion Criteria:

          1. Unstable angina (increase in frequency or severity of anginal episodes or development
             of chest pain at rest)

          2. significant obstructive disease (≥ 70%) in left main coronary artery, ostial LAD or
             three-vessel disease by MDCTA

          3. Significant heart failure (NYHA class III and IV)

          4. Current atrial fibrillation or Wolf-Parkinson-White (WPW) syndrome

          5. Allergy to beta-blocker in subjects with resting heart rate &gt; 65 bpm

          6. Systolic blood pressure &gt; 160 mm Hg

          7. Diastolic BP &gt; 100 mm Hg

          8. Persons with allergies to contrast material

          9. History of asthma if unable to tolerate beta blocker

         10. Allergy to iodinated contrast material or shellfish

         11. Allergy to nitroglycerin

         12. BMI &gt; 35 kg/m2 if female and &gt; 40 kg/m2 if male

         13. Body weight &gt; 350 lbs

         14. Use of drugs for weight loss [e.g. Xenical (orlistat), Meridia (sibutramine), Acutrim
             (phenylpropanolamine) or similar over-the counter medications] within three months of
             screening

         15. Surgery within 30 days of screening

         16. History of acquired immune deficiency syndrome or human immunodeficiency virus (HIV)

         17. Poor mental function or history of dementia/ Alzheimer's Disease or on medications
             used for treatment of dementia [e.g. Tacrine (Cognex), Rivastigmine (Exelon),
             Galantamine (Razadyne, Reminyl), Donepezil (Aricept), Memantine (Namenda)] or any
             other reason to expect patient difficulty in complying with the requirements of the
             study

         18. Medicine for erectile dysfunction within 72 hours prior to MDCTA

         19. History of significant chronic rheumatologic or other chronic inflammatory disease
             (including foot ulcers)

         20. Prior hemorrhagic stroke

         21. persons with known aspirin allergy

         22. Use of continuous oral corticosteroid treatment (more than 2 weeks), or patients
             requiring corticosteroids within 3 months

         23. Anti-diabetic medication including thiazolidinedione (pioglitazone or rosiglitazone),
             or insulin or Extendin-4 (Byetta)

         24. History of peptic ulcer or gastritis within 5 years

         25. Positive stool guaiac

         26. Hemoglobin 2 standard deviations below normal

         27. Low platelet count (2 standard deviations below normal)

         28. Known bleeding disorder

         29. Coumadin (warfarin compounds)

         30. History of type 1 diabetes and/or history of ketoacidosis

         31. Daily use of NSAIDS (including salsalate) for arthritis

         32. History of malignancy, except subjects who have been disease-free for greater than 5
             years, or whose only malignancy has been basal or squamous cell skin carcinoma

         33. History of drug or alcohol abuse, or current weekly alcohol consumption &gt;14 units/week
             (1 unit = 1 beer, 1 glass of wine, 1 mixed cocktail containing 1 ounce of alcohol)

         34. Use of probenecid (Benemid, Probalan), sulfinpyrazone (Anturane) or other uricosuric
             agents

         35. Chronic tinnitus.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francine Welty, MD</last_name>
    <role>Study Director</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Allison B. Goldfine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Joslin Diabetes Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ernest Schaefer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Melvin Clouse, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven E. Shoelson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Joslin Diabetes Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seacoast Cardiology</name>
      <address>
        <city>York</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center of Metrowest</name>
      <address>
        <city>Framingham</city>
        <state>Massachusetts</state>
        <zip>01702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Shore Internal Medicine</name>
      <address>
        <city>Milton</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newton-Wellesley Cardiology</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://joslin.org</url>
    <description>Home page for Joslin Diabetes Center, Boston, MA.</description>
  </link>
  <reference>
    <citation>Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006 Jul;116(7):1793-801. Review. Erratum in: J Clin Invest. 2006 Aug;116(8):2308.</citation>
    <PMID>16823477</PMID>
  </reference>
  <reference>
    <citation>Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008 Feb;31(2):289-94. Epub 2007 Oct 24.</citation>
    <PMID>17959861</PMID>
  </reference>
  <reference>
    <citation>Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J, Shoelson SE. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci. 2008 May;1(1):36-43. doi: 10.1111/j.1752-8062.2008.00026.x.</citation>
    <PMID>19337387</PMID>
  </reference>
  <reference>
    <citation>Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE; TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2010 Mar 16;152(6):346-57. doi: 10.7326/0003-4819-152-6-201003160-00004.</citation>
    <PMID>20231565</PMID>
  </reference>
  <reference>
    <citation>Goldfine AB, Fonseca V, Jablonski KA, Chen YD, Tipton L, Staten MA, Shoelson SE; Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2013 Jul 2;159(1):1-12. doi: 10.7326/0003-4819-159-1-201307020-00003.</citation>
    <PMID>23817699</PMID>
  </reference>
  <reference>
    <citation>Goldfine AB, Conlin PR, Halperin F, Koska J, Permana P, Schwenke D, Shoelson SE, Reaven PD. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia. 2013 Apr;56(4):714-23. doi: 10.1007/s00125-012-2819-3. Epub 2013 Jan 31.</citation>
    <PMID>23370525</PMID>
  </reference>
  <reference>
    <citation>Avadhani R, Fowler K, Barbato C, Thomas S, Wong W, Paul C, Aksakal M, Hauser TH, Weinger K, Goldfine AB. Glycemia and cognitive function in metabolic syndrome and coronary heart disease. Am J Med. 2015 Jan;128(1):46-55. doi: 10.1016/j.amjmed.2014.08.025. Epub 2014 Sep 16.</citation>
    <PMID>25220612</PMID>
  </reference>
  <reference>
    <citation>Goldfine AB, Shoelson SE. Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. J Clin Invest. 2017 Jan 3;127(1):83-93. doi: 10.1172/JCI88884. Epub 2017 Jan 3. Review.</citation>
    <PMID>28045401</PMID>
  </reference>
  <reference>
    <citation>Ridker PM. Informative Neutral Studies Matter-Why the Targeting Inflammation With Salsalate in Cardiovascular Disease (TINSAL-CVD) Trial Deserves Our Attention. JAMA Cardiol. 2016 Jul 1;1(4):423-4. doi: 10.1001/jamacardio.2016.0604.</citation>
    <PMID>27438318</PMID>
  </reference>
  <results_reference>
    <citation>Hauser TH, Salastekar N, Schaefer EJ, Desai T, Goldfine HL, Fowler KM, Weber GM, Welty F, Clouse M, Shoelson SE, Goldfine AB; Targeting Inflammation Using Salsalate in Cardiovascular Disease (TINSAL-CVD) Study Team. Effect of Targeting Inflammation With Salsalate: The TINSAL-CVD Randomized Clinical Trial on Progression of Coronary Plaque in Overweight and Obese Patients Using Statins. JAMA Cardiol. 2016 Jul 1;1(4):413-23. doi: 10.1001/jamacardio.2016.0605.</citation>
    <PMID>27438317</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2008</study_first_submitted>
  <study_first_submitted_qc>February 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2008</study_first_posted>
  <results_first_submitted>August 29, 2016</results_first_submitted>
  <results_first_submitted_qc>November 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 12, 2017</results_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Overweight</keyword>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>Salsalate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salicylsalicylic acid</mesh_term>
    <mesh_term>Sodium Salicylate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>340 subjects signed consent and were screened for eligibility.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1- Active Pharmacologic</title>
          <description>Salsalate
Salsalate: Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months</description>
        </group>
        <group group_id="P2">
          <title>2- Placebo</title>
          <description>Placebo
Placebo: Salsalate Placebo, seven tablets daily by mouth, divided into two doses, for 30 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1- Active Pharmacologic</title>
          <description>Salsalate
Salsalate: Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months</description>
        </group>
        <group group_id="B2">
          <title>2- Placebo</title>
          <description>Placebo
Placebo: Salsalate Placebo, seven tablets daily by mouth, divided into two doses, for 30 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="127"/>
            <count group_id="B2" value="124"/>
            <count group_id="B3" value="251"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.5" spread="6.8"/>
                    <measurement group_id="B2" value="60.1" spread="7.2"/>
                    <measurement group_id="B3" value="60.8" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Statin use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Non-calcified Plaque Volume in the Coronary Arteries Assessed by MDCTA From Baseline to 30 Months</title>
        <time_frame>Baseline to 30 months</time_frame>
        <population>Intention to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>1- Active Pharmacologic</title>
            <description>Salsalate
Salsalate: Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months</description>
          </group>
          <group group_id="O2">
            <title>2-Placebo</title>
            <description>Placebo
Placebo: Salsalate Placebo, seven tablets daily by mouth, divided into two doses, for 30 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Non-calcified Plaque Volume in the Coronary Arteries Assessed by MDCTA From Baseline to 30 Months</title>
          <population>Intention to Treat</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-8" upper_limit="7"/>
                    <measurement group_id="O2" value="0" lower_limit="-7" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Metabolic Syndrome Assessed by Measures by Waist/Hip Ratio, Systolic and Diastolic Blood Pressure, Lipid Profiles (Total Cholesterol, Triglycerides, HDL and LDL), and Abdominal Adiposity Quantitated by Computerized Tomography</title>
        <time_frame>Baseline to 30 mo</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction of Mediators of Inflammation in the Circulation (Such as CRP), and Markers of Oxidative Stress.</title>
        <time_frame>baseline to 30 mo</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction of Insulin Resistance Assessed by Fasting Insulin and Homeostasis Model Assessment of Insulin Resistance (HOMA-IR).</title>
        <time_frame>baseline to 30 mo</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction of Inflammation in the Liver Associated With Nonalcoholic Steatohepatitis (NASH), and Reduction of Fatty Liver Quantitated by Computerized Tomography and Levels of AST and ALT as Markers of Liver Inflammation Related to NASH.</title>
        <time_frame>baseline to 30 mo</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Rates of Addition of Anti-hypertensive, Diabetic, or Lipid Lowering Medication.</title>
        <time_frame>baseline to 30 mo</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Numbers of Persons With Metabolic Syndrome Who Progress to Diabetes Between Groups.</title>
        <time_frame>baseline to 30 mo</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Numbers of Persons Who Regress From ATPIII Metabolic Syndrome Criteria (for Those With Metabolic Syndrome at Baseline)</title>
        <time_frame>baseline to 30 mo</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Vitamin D Status and Coronary Calcification, as Well as With Insulin Resistance (HOMA-IR), Beta-cell Function (HOMA-%Beta), and Serum Levels of Inflammatory Cytokines and Adhesion Molecules, Known to be Related to CVD Risk.</title>
        <time_frame>Baseline evaluation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determination of Whether Baseline Vitamin D Levels Predict Clinical Response to Salsalate, and Whether Hypovitaminosis D is Associated With Plaque Progression.</title>
        <time_frame>baseline to 30 mo</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1- Active Pharmacologic</title>
          <description>Salsalate
Salsalate: Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months</description>
        </group>
        <group group_id="E2">
          <title>2- Placebo</title>
          <description>Placebo
Placebo: Salsalate Placebo, seven tablets daily by mouth, divided into two doses, for 30 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatologic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and Labyrinth</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Mouth sores</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Allison Goldfine</name_or_title>
      <organization>Joslin Diabetes Center</organization>
      <phone>617-309-2400</phone>
      <email>allison.goldfine@joslin.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

